Department of Internal Medicine and Cardiology, University of Leipzig Heart Center, Struempellstrasse 39, 04289 Leipzig, Germany
Bern University Hospital, Bern, Switzerland.
Eur Heart J. 2014 Oct 7;35(38):2672-84. doi: 10.1093/eurheartj/ehu162. Epub 2014 Mar 28.
Transcatheter aortic valve implantation has become an alternative to surgery in higher risk patients with symptomatic aortic stenosis. The aim of the ADVANCE study was to evaluate outcomes following implantation of a self-expanding transcatheter aortic valve system in a fully monitored, multi-centre 'real-world' patient population in highly experienced centres.
Patients with severe aortic stenosis at a higher surgical risk in whom implantation of the CoreValve System was decided by the Heart Team were included. Endpoints were a composite of major adverse cardiovascular and cerebrovascular events (MACCE; all-cause mortality, myocardial infarction, stroke, or reintervention) and mortality at 30 days and 1 year. Endpoint-related events were independently adjudicated based on Valve Academic Research Consortium definitions. A total of 1015 patients [mean logistic EuroSCORE 19.4 ± 12.3% [median (Q1,Q3), 16.0% (10.3, 25.3%)], age 81 ± 6 years] were enrolled. Implantation of the CoreValve System led to a significant improvement in haemodynamics and an increase in the effective aortic valve orifice area. At 30 days, the MACCE rate was 8.0% (95% CI: 6.3-9.7%), all-cause mortality was 4.5% (3.2-5.8%), cardiovascular mortality was 3.4% (2.3-4.6%), and the rate of stroke was 3.0% (2.0-4.1%). The life-threatening or disabling bleeding rate was 4.0% (2.8-6.3%). The 12-month rates of MACCE, all-cause mortality, cardiovascular mortality, and stroke were 21.2% (18.4-24.1%), 17.9% (15.2-20.5%), 11.7% (9.4-14.1%), and 4.5% (2.9-6.1%), respectively. The 12-month rates of all-cause mortality were 11.1, 16.5, and 23.6% among patients with a logistic EuroSCORE ≤10%, EuroSCORE 10-20%, and EuroSCORE >20% (P< 0.05), respectively.
The ADVANCE study demonstrates the safety and effectiveness of the CoreValve System with low mortality and stroke rates in higher risk real-world patients with severe aortic stenosis.
经导管主动脉瓣植入术已成为有症状的主动脉瓣狭窄高危患者的手术替代方法。 ADVANCE 研究的目的是评估在经验丰富的中心中,在全面监测的多中心“真实世界”患者人群中使用自扩张经导管主动脉瓣系统植入后的结果。
纳入因外科手术风险较高而决定植入 CoreValve 系统的严重主动脉瓣狭窄且具有较高手术风险的患者。终点是主要不良心血管和脑血管事件(MACCE;全因死亡率、心肌梗死、卒中和再介入)的复合终点以及 30 天和 1 年的死亡率。根据 Valve Academic Research Consortium 的定义,对与终点相关的事件进行独立裁决。共纳入 1015 例患者[平均 logistic EuroSCORE 19.4±12.3%[中位数(Q1,Q3),16.0%(10.3,25.3%)],年龄 81±6 岁]。植入 CoreValve 系统可显著改善血液动力学并增加有效主动脉瓣口面积。30 天时,MACCE 发生率为 8.0%(95%CI:6.3-9.7%),全因死亡率为 4.5%(3.2-5.8%),心血管死亡率为 3.4%(2.3-4.6%),卒中图发生率为 3.0%(2.0-4.1%)。危及生命或致残性出血发生率为 4.0%(2.8-6.3%)。MACCE、全因死亡率、心血管死亡率和卒中的 12 个月发生率分别为 21.2%(18.4-24.1%)、17.9%(15.2-20.5%)、11.7%(9.4-14.1%)和 4.5%(2.9-6.1%)。Logistic EuroSCORE≤10%、10-20%和>20%的患者 12 个月全因死亡率分别为 11.1%、16.5%和 23.6%(P<0.05)。
ADVANCE 研究表明,在严重主动脉瓣狭窄的高危真实世界患者中,CoreValve 系统具有较低的死亡率和卒中图发生率,安全性和有效性得到了证实。